Zymo Research Obtains CE IVD Mark for its Quick SARS-CoV-2 Multiplex Kit
AsiaNet 86513
IRVINE, California, Nov. 10, 2020 /PRNewswire=KYODO JBN/
-- Low cost, high-sensitivity diagnostic test for COVID-19 detection
Zymo Research announced today that it obtained a CE IVD mark for the Quick
SARS-CoV-2 Multiplex Kit in compliance with the Directive 98/79/EC of the
European Parliament and of the Council of 27 October 1998 on in vitro
diagnostic medical devices. The Quick SARS-CoV-2 Multiplex Kit (
) is a real-time reverse transcription PCR (RT-PCR) test used for the
qualitative detection of nucleic acids from SARS-CoV-2 (the virus that causes
COVID-19) in upper and lower respiratory specimens taken from patients whose
healthcare providers suspect have contracted COVID-19.
Photo -
Logo - https://mma.prnewswire.com/media/364743/Zymo_Research_Corp_Logo.jpg
The Quick SARS-CoV-2 Multiplex Kit has a limit of detection (LoD) of 10-virus
copies/reaction and up to 382 samples can be analyzed for each RT-PCR run. This
high performance, combined with increased throughput, competitive pricing, and
a widespread distribution network, makes this test among the best on the
market.* The kit is ideal for clinical diagnostic labs that currently offer or
want to offer COVID-19 testing including hospitals, universities, research
centers, as well as laboratories that perform environmental surveillance for
SARS-CoV-2.
The kit is easy to use in any lab equipped with RT-PCR instrumentation that is
capable of detecting HEX (or VIC) and Quasar 670 (or Cy5) fluorophores. It
comes in multiple formats (100-, 1,000-, or 10,000-test quantities), which make
it amenable for use in small or large laboratories. With a strong international
distribution network and a high production capacity, Zymo Research is capable
of meeting the high-volume reagent demands of laboratories around the globe.
"With over 46 million** COVID-19 cases reported worldwide, our goal is to help
stop the spread of SARS-CoV-2 by enabling increased testing," said Dr. Paolo
Piatti, Senior Scientist at Zymo Research. "The CE IVD mark, along with the
competitive pricing, makes this high-quality product readily accessible to
laboratories and ultimately expands the availability of COVID-19 testing to
many more facilities throughout the world."
For more information about Zymo Research's Quick SARS-CoV-2 Multiplex Kit and
workflow, please visit their website (
) or contact them via email at covid19requests@zymoresearch.com.
About Zymo Research Corp.
Zymo Research is a privately owned company that has been serving the scientific
and diagnostics community with state-of-the-art molecular biology tools since
1994. "The Beauty of Science is to Make Things Simple" is their motto,
reflected in all of their products, from epigenetics to DNA/RNA purification
technologies. Historically recognized as the leader in epigenetics, Zymo
Research is breaking boundaries with novel solutions for sample collection,
microbiomic measurements, diagnostic devices, and NGS technologies that are
high quality and simple to use. Follow Zymo Research on Facebook (
), LinkedIn (
), Twitter (
), and Instagram (
).
References
*
**https://www.statista.com/statistics/1087466/covid19-cases-recoveries-deaths-wo
rldwide/
SOURCE: Zymo Research Corp.
CONTACT: Marketing Department, Zymo Research Corp., 949.679.1190,
marketing@zymoresearch.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
